Legato Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Legato Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,354	Closed	-$99.5K	–	517
2022 Q4	$99.5K	Buy	+15,354	New	+$127K	0.02%	477
2021 Q2	–	Sell	-94,407	Closed	-$1M	–	371
2021 Q1	$1M	Sell	94,407 -116,253	-55%	-$1.31M	0.19%	108
2020 Q4	$2.29M	Sell	210,660 -1,760	-0.8%	-$18.2K	0.43%	84
2020 Q3	$2.06M	Sell	212,420 -18,550	-8%	-$177K	0.46%	73
2020 Q2	$1.84M	Hold	230,970	–	–	0.37%	69
2020 Q1	$2.01M	Hold	230,970	–	–	0.58%	41
2019 Q4	$2.61M	Hold	230,970	–	–	0.54%	41
2019 Q3	$2.1M	Hold	230,970	–	–	0.39%	79
2019 Q2	$2.16M	Buy	230,970 +54,750	+31%	+$553K	0.4%	75
2019 Q1	$2.16M	Buy	176,220 +86,890	+97%	+$1.06M	0.71%	56
2018 Q4	$1.06M	Buy	+89,330	New	+$1.23M	0.22%	110

Other funds holding LFCR

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Legato Capital Management's LFCR Position: Q1 2023 in Review

Legato Capital Management sold out of Lifecore Biomedical (LFCR) in Q1 2023, closing a stake of 15,354 shares — an estimated $99.5K sold.

Legato Capital Management first reported a position in LFCR in Q4 2018 and held it in 11 quarters. The position peaked at $2.61M in Q4 2019. 82 funds tracked by Wall St. Rank hold LFCR as of Q1 2023.

Legato Capital Management reported no remaining Lifecore Biomedical position as of Q1 2023 after selling out during the quarter.
Legato Capital Management sold 15,354 Lifecore Biomedical shares in Q1 2023, an estimated $99.5K.
Legato Capital Management first reported a position in Lifecore Biomedical in Q4 2018 and held it in 11 quarters.
Legato Capital Management's Lifecore Biomedical position peaked at $2.61M in Q4 2019.
82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2023.

Based on Legato Capital Management's 13F filing for Q1 2023, filed 25 May 2023.